Position statement : The need for EU legislation to require disclosure and labelling of the composition of medical devices
Herman, Anne (Cliniques universitaires Saint-Luc, Brussels)
Uter, Wolfgang (Univ. Erlangen/Nürnberg)
Rustemeyer, Thomas (Amsterdam Universitair Medische Centra (Amsterdam, Països Baixos))
Matura, M. (Skaraborgs Hospital Skövde)
Aalto-Korte, K. (Finnish Institute of Occupational Health, Helsinki)
Duus Johansen, J. (Herlev-Gentofte Hospital)
Gonçalo, Margarida (Centro Hospitalar e Universitário de Coimbra (Coimbra, Portugal))
White, I. R. (St. John's Institute of Dermatology, London)
Balato, Anna (University of Naples Federico II)
Giménez-Arnau, Ana M 1961- (Universitat Autònoma de Barcelona. Departament de Medicina)
Brockow, Knut (Technical University of Munich)
Mortz, Charlotte G (Odense Research Center for Anaphylaxis)
Mahler, Vera (Paul-Ehrlich-Institut)
Goossens, A. (University Hospitals Leuven (Bèlgica))

Data:	2021
Resum:	In recent years, skin reactions secondary to the use of medical devices (MD), such as allergic contact dermatitis have increasingly been observed (e. g. to continuous blood sugar monitoring systems, insulin pumps, wound dressings, medical gloves, etc. ): this is regarded as a developing epidemic. Lack of labelling of the composition of MD, as well as frequent lack of cooperation of manufacturers to disclose this relevant information, even when contacted by the clinician for the individual case of an established adverse reaction, significantly impede patient care. To advocate for full ingredient labelling in the implementation of EU regulation for MD. This position paper reviews the scientific literature, the current regulatory framework adopted for MD to date, and the likely impact, including some costs data in case of the absence of such labelling. Efforts made by several scientific teams, who are trying to identify the culprit of such adverse effects, either via asking for cooperation from companies, or using costly chemical analyses of MD, can only partly, and with considerable delay, compensate for the absence of meaningful information on the composition of MD; hence, patient management is compromised. Indeed, without knowing the chemical substances present, physicians are unable to inform patients about which substances they should avoid, and which alternative MD may be suitable/tolerated. There is an urgent need for full and accurate labelling of the chemical composition of MD in contact with the human body.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; altres ; Versió publicada
Publicat a:	Journal of the European Academy of Dermatology and Venereology, Vol. 35 (may 2021) , p. 1444-1448, ISSN 1468-3083

DOI: 10.1111/jdv.17238
PMID: 33955077

5 p, 193.3 KB

El registre apareix a les col·leccions:
Articles > Articles publicats